Generic Tybost Availability
Last updated on Apr 10, 2025.
Tybost is a brand name of cobicistat, approved by the FDA in the following formulation(s):
TYBOST (cobicistat - tablet;oral)
-
Manufacturer: GILEAD SCIENCES INC
Approval date: September 24, 2014
Strength(s): 150MG [RLD]
Is there a generic version of Tybost available?
No. There is currently no therapeutically equivalent version of Tybost available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tybost. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent 10,039,718
Issued: August 7, 2018
Inventor(s): Koziara Joanna M. & Menning Mark M. & Strickley Robert G. & Yu Richard & Kearney Brian P. & Mathias Anita A.
Assignee(s): Gilead Sciences, Inc.The invention provides a composition comprising, a compound of formula (I):
Patent expiration dates:
- October 6, 2032✓
- October 6, 2032
-
Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent 10039718*PE
Issued: August 7, 2018
Inventor(s): Koziara Joanna M. & Menning Mark M. & Strickley Robert G. & Yu Richard & Kearney Brian P. & Mathias Anita A.
Assignee(s): Gilead Sciences, Inc.The invention provides a composition comprising, a compound of formula (I):
Patent expiration dates:
- April 6, 2033
- April 6, 2033
-
Modulators of pharmacokinetic properties of therapeutics
Patent 8,148,374
Issued: April 3, 2012
Inventor(s): Desai Manoj C. & Liu Hongtao & Xu Lianhong
Assignee(s): Gilead Sciences, Inc.The present application provides for a compound of Formula IV,
Patent expiration dates:
- September 3, 2029✓✓✓
- September 3, 2029
-
Modulators of pharmacokinetic properties of therapeutics
Patent 8148374*PED
Issued: April 3, 2012
Inventor(s): Desai Manoj C. & Liu Hongtao & Xu Lianhong
Assignee(s): Gilead Sciences, Inc.The present application provides for a compound of Formula IV,
Patent expiration dates:
- March 3, 2030✓
- March 3, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 22, 2026 - INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
More about Tybost (cobicistat)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antiviral boosters
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.